Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2025)
Historic Operating Leases for Protalix BioTherapeutics (PLX) over the last 7 years, with Q3 2025 value amounting to $6.8 million.
- Protalix BioTherapeutics' Operating Leases rose 6235.63% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 6235.63%. This contributed to the annual value of $4.0 million for FY2024, which is 1287.6% down from last year.
- According to the latest figures from Q3 2025, Protalix BioTherapeutics' Operating Leases is $6.8 million, which was up 6235.63% from $3.9 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Operating Leases ranged from a high of $6.8 million in Q3 2025 and a low of $3.8 million during Q1 2025
- Moreover, its 5-year median value for Operating Leases was $4.3 million (2024), whereas its average is $4.4 million.
- Data for Protalix BioTherapeutics' Operating Leases shows a peak YoY increase of 6235.63% (in 2025) and a maximum YoY decrease of 1529.23% (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Operating Leases stood at $4.4 million in 2021, then dropped by 4.73% to $4.2 million in 2022, then rose by 10.84% to $4.6 million in 2023, then dropped by 12.88% to $4.0 million in 2024, then soared by 68.41% to $6.8 million in 2025.
- Its Operating Leases was $6.8 million in Q3 2025, compared to $3.9 million in Q2 2025 and $3.8 million in Q1 2025.